ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Predictive Medicine Research

This study is currently recruiting participants.
Verified by Emory University, October 2006

Sponsors and Collaborators: Emory University
Woodruff Foundation
Information provided by: Emory University
ClinicalTrials.gov Identifier: NCT00384761
  Purpose

To establish normal values by age, race, and gender of novel markers of risk in healthy subjects necessary to predict precise risk of cardiovascular disease in an individual


Condition Phase
Atherolsclerosis, Endothelial Dysfunction
Phase I

U.S. FDA Resources

Study Type:   Observational
Study Design:   Screening, Cross-Sectional, Defined Population, Prospective Study
Official Title:   Predictive Medicine Research: Investigation of Predictors of Health, Sub-Clincal and Clinical Organ System Disease

Further study details as provided by Emory University:

Study Start Date:   March 2006
Estimated Study Completion Date:   November 2008

Detailed Description:

Introduction

As a person ages their chance of developing certain diseases such as hardening of the arteries (atherosclerosis), diabetes, depression, osteoporosis and memory loss (Alzheimer’s disease) increases. One of the theories that might explain why age increases the risk of developing these diseases involves a concept called oxidative stress. Oxidative stress is a process that occurs inside the cells in our body. All the cells in our body are constantly undergoing various biochemical reactions, which are important to the cell’s life cycle. Byproducts of these biochemical reactions are molecules called free radicals or pro-oxidants. Pro-oxidants can be very damaging to the cell and lead to cell death. Cells also have molecules called antioxidants, which neutralize the pro-oxidants and protect the cell so it can continue functioning normally. Oxidative stress occurs when there is an imbalance in the pro-oxidants as compared with the antioxidants. Other studies have shown that diseases such as hardening of the arteries, depression, osteoporosis and Alzheimer’s are associated with elevated levels of free radicals or pro-oxidants inside the cells. It is now possible to measure the levels of pro-oxidants in the cells using blood tests.

Objectives

The purpose of this study is to determine how reliable and reproducible these measurements are and also to define a “normal” value or range of values in healthy people. It is our hope that after we are able to define the normal range of values for oxidative stress we can then look at people with the aforementioned diseases and measure their levels of oxidative stress looking for a correlation between the two. If we can show a direct correlation between level of oxidative stress and these diseases we can begin trying to develop medicines that can target this area and hopefully prevent or lessen the degree of these diseases.

Tests and Evaluations

In this study we are looking for healthy participants age 30 and older who will undergo blood tests that will allow us to measure markers of oxidative stress. Participants will also undergo tests specifically designed to look for evidence of early multi-organ disease. These exams will include an evaluation of lung function (spirometry test), exercise capacity (using a stationary bike), bone density scan looking for osteoporosis, ultrasound of the artery of the neck (carotid) and artery of the arm (brachial), nerve conduction study, bio-impedance (Body fact composition) and several questionnaires to assess memory and mood. The participants require one screening visit and a follow up visit to undergo the tests.

  Eligibility
Ages Eligible for Study:   30 Weeks to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Ages 30-90+
  • Normal performance status
  • LDL cholesterol level <120 mg/dl
  • Fasting blood glucose <99 mg/dL
  • Blood pressure <135 mmHg systolic and <85 mmHg diastolic
  • Non-smoker for at least 5 years
  • BMI >19 and <26; stable body weight
  • Free of neurological and psychological (Axis I) disorders for at least three years.

Exclusion Criteria:

  • Age <30
  • Any oral antioxidants in the previous 2 weeks
  • On lipid lowering medication in the past 8 weeks
  • History of substance abuse
  • Current cancer or history of cancer except basal cell cancer
  • Any heart disease except for corrected congenital ht disease
  • History of neurological disease
  • History of chronic GI disorders
  • History of inflammatory joint disorders
  • Known endocrine disorders
  • History of Chronic Pulmonary diseases e.g. COPD
  • Acute illness such as infection in the previous 4 weeks
  • Creatinine > 2
  • Liver enzymes >1.5X normal
  • Anemia (Hemoglobine < 12.5) or chronic hematological disorder
  • Physical limitation and sedentary status for any reason
  • LDL cholesterol > 120
  • Fasting Glucose > 99
  • BP >135/85 on 3 repeated measures
  • Current smoker or smoker in the last 5 years
  • History of depression
  • Inability to give informed consent

For more information or patient referral call Johnson Pereira 404-275-0034, Rajinder Grover 404-686-7063, Muhammad Amer 404-805-4771 or Salman Sher 404-587-2667

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00384761

Contacts
Contact: Johnson Pereira, MD     404-275-0034     jpereir@emory.edu    

Locations
United States, Georgia
Emory University Hospital     Recruiting
      Atlanta, Georgia, United States, 30322
      Contact: Johnson Pereira, MD     404-275-0034        
      Principal Investigator: Arshed Quyyumi, MD, FACP,            

Sponsors and Collaborators
Emory University
Woodruff Foundation

Investigators
Principal Investigator:     Arshed Quyyumi, MD     Emory Hospital    
Study Director:     Muhammad Amer, MD     Emory University    
  More Information


Study ID Numbers:   1190-2005, PreMed 6012
First Received:   October 3, 2006
Last Updated:   October 5, 2006
ClinicalTrials.gov Identifier:   NCT00384761
Health Authority:   United States: Institutional Review Board

ClinicalTrials.gov processed this record on October 29, 2008




Links to all studies - primarily for crawlers